OncoMatch/Clinical Trials/NCT05341557
A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma
Is NCT05341557 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies BPI-371153 for advanced solid tumor.
Treatment: BPI-371153 — A first-in-human study to evaluate the safety, tolerability and maximum tolerated dose (MTD) and establish the recommended phase 2 dose (RP2D) of BPI-371153, a PD-L1 Inhibitor, in patients with advanced solid tumors or relapsed/refractory lymphoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Non-Hodgkin Lymphoma
Hodgkin Lymphoma
Non-Small Cell Lung Carcinoma
Hepatocellular Carcinoma
Disease stage
Required: Stage III, IV, RELAPSED
locally advanced or metastatic solid tumor; relapsed/refractory lymphoma; locally advanced or relapsed/metastatic Non-Driver Mutation NSCLC; HCC with Child-Pugh A or B(≤ 7 points)
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: standard therapy
disease progression after standard therapy, intolerable to standard therapy, refuse to standard therapy or for whom no standard therapy exists
Cannot have received: immune checkpoint inhibitor (anti-PD-1, anti-PD-L1, anti-PD-L2)
Prior immune checkpoint inhibition with anti-programmed cell death-1 (PD1)/programmed death ligand-1(PD-L1) or programmed death ligand-2(PD-L2) therapy
Cannot have received: T cell targeting agent
Prior other specific T cell targeting agents
Lab requirements
Blood counts
Adequate organ function
Kidney function
Adequate organ function
Liver function
HCC with Child-Pugh A or B(≤ 7 points)
Adequate organ function; HCC with Child-Pugh A or B(≤ 7 points)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05341557 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior immune checkpoint inhibitor, T cell targeting agent disqualifies patients from enrollment.
What disease stage is eligible?
Stage III or IV or RELAPSED is required.
Is there an age limit?
Yes. Patients must be 65 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages